Thompson Siegel & Walmsley LLC raised its holdings in Elevance Health, Inc. (NYSE:ELV – Free Report) by 7.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 21,230 shares of the company’s stock after buying an additional 1,475 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in Elevance Health were worth $7,442,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sound View Wealth Advisors Group LLC boosted its position in Elevance Health by 3.0% during the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,011 shares of the company’s stock valued at $354,000 after purchasing an additional 29 shares during the last quarter. Fulton Breakefield Broenniman LLC boosted its holdings in shares of Elevance Health by 3.6% in the 4th quarter. Fulton Breakefield Broenniman LLC now owns 825 shares of the company’s stock valued at $289,000 after buying an additional 29 shares during the last quarter. Perigon Wealth Management LLC grew its stake in shares of Elevance Health by 2.2% in the fourth quarter. Perigon Wealth Management LLC now owns 1,371 shares of the company’s stock valued at $481,000 after buying an additional 29 shares in the last quarter. Savvy Advisors Inc. grew its stake in shares of Elevance Health by 3.2% in the fourth quarter. Savvy Advisors Inc. now owns 979 shares of the company’s stock valued at $343,000 after buying an additional 30 shares in the last quarter. Finally, CoreCap Advisors LLC increased its holdings in Elevance Health by 6.1% during the fourth quarter. CoreCap Advisors LLC now owns 557 shares of the company’s stock worth $195,000 after buying an additional 32 shares during the last quarter. 89.24% of the stock is owned by institutional investors.
Elevance Health Stock Up 2.4%
Shares of NYSE ELV opened at $402.69 on Tuesday. The stock has a market capitalization of $87.45 billion, a P/E ratio of 17.13, a PEG ratio of 2.22 and a beta of 0.66. The stock’s fifty day moving average is $345.97 and its 200 day moving average is $339.77. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $408.00. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48.
Elevance Health Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 annualized dividend and a yield of 1.7%. Elevance Health’s dividend payout ratio is presently 29.26%.
Analyst Upgrades and Downgrades
ELV has been the subject of a number of analyst reports. Weiss Ratings raised shares of Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, May 18th. Robert W. Baird upped their price objective on Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a research note on Thursday, April 23rd. Sanford C. Bernstein lifted their target price on Elevance Health from $384.00 to $424.00 and gave the stock an “outperform” rating in a research note on Friday, April 24th. The Goldman Sachs Group increased their price target on Elevance Health from $350.00 to $370.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Finally, Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $407.05.
Get Our Latest Stock Analysis on ELV
Elevance Health Company Profile
Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.
Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.
Read More
- Five stocks we like better than Elevance Health
- Why 1 Little-Known ETF Is Riding the AI Chip Shortage
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
